Federated Hermes’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Federated Hermes’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,180	Closed	-$438K	–	2406
2021 Q4	$438K	Sell	3,180 -241,146	-99%	-$30.7M	﹤0.01%	1515
2021 Q3	$33.9M	Buy	244,326 +171,546	+236%	+$21.4M	0.06%	360
2021 Q2	$7.07M	Buy	72,780 +72,642	+52,639%	+$5.9M	0.01%	750
2021 Q1	$9K	Sell	138 -105,284	-100%	-$8.52M	﹤0.01%	2020
2020 Q4	$9.04M	Buy	105,422 +2,101	+2%	+$178K	0.02%	671
2020 Q3	$6.72M	Buy	103,321 +11,823	+13%	+$775K	0.02%	663
2020 Q2	$6.69M	Buy	+91,498	New	+$4.87M	0.02%	635
2019 Q3	–	Sell	-91,638	Closed	-$4.01M	–	2382
2019 Q2	$4.01M	Sell	91,638 -154,120	-63%	-$8.69M	0.01%	849
2019 Q1	$12.6M	Buy	245,758 +219,538	+837%	+$9.48M	0.03%	478
2018 Q4	$970K	Buy	+26,220	New	+$945K	﹤0.01%	1298

Other funds holding BHVN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Federated Hermes's BHVN Position: Q1 2022 in Review

Federated Hermes sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2022, closing a stake of 3,180 shares — an estimated $438K sold.

Federated Hermes first reported a position in BHVN in Q4 2018 and held it in 10 quarters. The position peaked at $33.9M in Q3 2021. 307 funds tracked by Wall St. Rank hold BHVN as of Q1 2022.

Federated Hermes reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2022 after selling out during the quarter.
Federated Hermes sold 3,180 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2022, an estimated $438K.
Federated Hermes first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2018 and held it in 10 quarters.
Federated Hermes's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $33.9M in Q3 2021.
307 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2022.

Based on Federated Hermes's 13F filing for Q1 2022, filed 13 May 2022.